Available Treatment Options in DLBCL with 2 or More Relapses

Soligenix has requested a Type A meeting with the FDA to get clarity around the item needed to complete the new drug application of SGX301 for patients with early-stage cutaneous T-cell lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

While JCAR021 showed durable responses, there was a high rate of neurotoxicity when given at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma.